HROW Harrow, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
20:14
Oct 13
Oct 13
15:18
Aug 12
Aug 12
11:55
Jan 19
Jan 19
r/ValueInvesting
HROW's VEVYE coverage switch drives margin expansion and share gains.
Author is bullish on Harrow (HROW) after its VEVYE drug won preferred status on CVS Caremark starting January 1, automatically switching Xiidra patients to VEVYE. Previously without mainstream insurance, HROW had 12% market share at $59/month cash; insured sales could be over $200, profit margins more than 4x, and market share could reach 20% this year.
About HROW Investor Commentary
Across the available history and selected sources, Buzzberg tracks HROW (Harrow, Inc.) across 4 sources: 4 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 9% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 45 total trade ideas tracked. Latest voices: moodywriter13, mvcinvesting, u/conangreer18.